SCHEMBL1866287

SCHEMBL1866287

Cc1c(NC(=O)OC(C)(C)C)ccnc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.58
METAP1 P53582 1/20 0.43
CYP17A1 P05093 2/20 0.42
AAK1 Q2M2I8 3/20 0.41
LCK P06239 1/20 0.39
P2RX7 Q99572 1/20 0.39
BRD9 Q9H8M2 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PIK3CD O00329 1/20 0.38
ABL1 P00519 1/20 0.38
EGFR P00533 1/20 0.38
HCK P08631 1/20 0.38
SRC P12931 1/20 0.38
KDR P35968 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
EPHB4 P54760 1/20 0.38
PRKDC P78527 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7021440 0.96 ATR (0.54) ATRMETAP1CYP17A1AAK1LCK
SCHEMBL30888170 0.87 ATR (0.59) ATRMETAP1CYP17A1AAK1LCK
SCHEMBL4393718 0.85 ATR (0.58) ATRMETAP1CYP17A1AAK1LCK
SCHEMBL797495 0.84 ATR (0.56) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL29418624 0.84 ATR (0.56) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL10085201 0.83 ATR (0.55) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL21500055 0.83 ATR (0.59) ATRMETAP1CYP17A1AAK1LCK
SCHEMBL1058106 0.83 ATR (0.59) ATRMETAP1CYP17A1AAK1MAPKAPK2
SCHEMBL1059432 0.83 ATR (0.55) ATRMETAP1CYP17A1AAK1BRD9
SCHEMBL31701240 0.83 ATR (0.59) ATRMETAP1CYP17A1AAK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947684-B2 anticoagulants; immunomoderators; antiinflammatory agents AVENTIS PHARMACEUTICALS INC. (US) 2011-05-24 US disclosed
US-20040220171-A1 1-Aroyl-piperidinyl benzamidines AVENTIS PHARMACEUTICALS INC 2004-11-04 US disclosed
EP-1278732-A1 1-AROYL-PIPERIDINYL BENZAMIDINES Aventis Pharmaceuticals Inc. (US) 2003-01-29 EP disclosed
US-20020045613-A1 1-aroyl-piperidinyl benzamidines AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-04-18 US disclosed
WO-2001081310-A1 1-AROYL-PIPERIDINYL BENZAMIDINES AVENTIS PHARMACEUTICALS INC. (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220171-A1 1-Aroyl-piperidinyl benzamidines TPSAB1, TPSB2, CMA1 ATR 2323/4885METAP1 56/4885CYP17A1 750/4885
US-20020045613-A1 1-aroyl-piperidinyl benzamidines TPSAB1, TPSB2, CMA1 ATR 2323/4885METAP1 56/4885CYP17A1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.